Intriguingly, although the MMP11 SNP rs131451 genotypic variants showed no statistical significant association to the clinical status in 431 UCC patients (Table 3), we found that carriers with the MMP11 rs131451 “CC” genotype had a lower risk (The odds ratio (OR) = 0.375, 95% confidence intervals (CI) = 0.159 − 0.887) to develop advanced-stage of tumor t status in 166 UCC patients among age ≤ 65 years old compared with the MMP11 rs131451 “CT + TT” genotype (p = 0.026, Table 4). This evidence concerns the gene MMP11 and neoplasm.